Moomoo AI 已提取核心信息
Panbela Therapeutics, Inc. has submitted a response to the U.S. Securities and Exchange Commission (SEC) regarding comments on its Registration Statement on Form S-1, initially filed on January 4, 2024. The correspondence, dated January 22, 2024, addresses the SEC's feedback from a letter dated January 9, 2024, and includes an Amendment No. 1 to the Registration Statement. The SEC had requested revisions to the cover page of the prospectus to specify the volume of Class E, Class F, and Pre-Funded Warrants being registered, as well as to disclose the termination date of the offering. Panbela Therapeutics has made the necessary revisions, including the quantities of the warrants and the specific offering termination date. The company has engaged Roth Capital Partners as its placement agent for the offering, which is being conducted on a best efforts basis. The response to the SEC was reviewed and approved by Panbela Therapeutics and includes input from the company's CEO, Jennifer K. Simpson, CFO Susan Horvath, and legal counsel from Faegre Drinker Biddle & Reath LLP.
Panbela Therapeutics, Inc. has submitted a response to the U.S. Securities and Exchange Commission (SEC) regarding comments on its Registration Statement on Form S-1, initially filed on January 4, 2024. The correspondence, dated January 22, 2024, addresses the SEC's feedback from a letter dated January 9, 2024, and includes an Amendment No. 1 to the Registration Statement. The SEC had requested revisions to the cover page of the prospectus to specify the volume of Class E, Class F, and Pre-Funded Warrants being registered, as well as to disclose the termination date of the offering. Panbela Therapeutics has made the necessary revisions, including the quantities of the warrants and the specific offering termination date. The company has engaged Roth Capital Partners as its placement agent for the offering, which is being conducted on a best efforts basis. The response to the SEC was reviewed and approved by Panbela Therapeutics and includes input from the company's CEO, Jennifer K. Simpson, CFO Susan Horvath, and legal counsel from Faegre Drinker Biddle & Reath LLP.
Panbela Therapeutics, Inc.已就其最初于2024年1月4日提交的S-1表格注册声明的评论向美国证券交易委员会（SEC）提交了回应。这封日期为2024年1月22日的信函回应了美国证券交易委员会对2024年1月9日信函的反馈，其中包括注册声明的第1号修正案。美国证券交易委员会已要求修改招股说明书的封面，以具体说明注册的E类、F类和预融资认股权证的数量，并披露发行的终止日期。Panbela Therapeutics已进行了必要的修改，包括认股权证的数量和具体的发行终止日期。该公司已聘请Roth Capital Partners作为此次发行的配售代理，该发行正在尽最大努力进行。对美国证券交易委员会的回应已获得Panbela Therapeutics的审查和批准，其中包括该公司首席执行官詹妮弗·辛普森、首席财务官苏珊·霍瓦斯以及Faegre Drinker Biddle & Reath LLP法律顾问的意见。
Panbela Therapeutics, Inc.已就其最初于2024年1月4日提交的S-1表格注册声明的评论向美国证券交易委员会（SEC）提交了回应。这封日期为2024年1月22日的信函回应了美国证券交易委员会对2024年1月9日信函的反馈，其中包括注册声明的第1号修正案。美国证券交易委员会已要求修改招股说明书的封面，以具体说明注册的E类、F类和预融资认股权证的数量，并披露发行的终止日期。Panbela Therapeutics已进行了必要的修改，包括认股权证的数量和具体的发行终止日期。该公司已聘请Roth Capital Partners作为此次发行的配售代理，该发行正在尽最大努力进行。对美国证券交易委员会的回应已获得Panbela Therapeutics的审查和批准，其中包括该公司首席执行官詹妮弗·辛普森、首席财务官苏珊·霍瓦斯以及Faegre Drinker Biddle & Reath LLP法律顾问的意见。
有用
没用
该公告为独立文件：